University of Nebraska Medical Center

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Association of American Physicians, Faculty, American College, ASCO, Dean, MD Anderson Cancer Center, Vice, Clinical professor, Hematology, American Society of Clinical Oncology, Advisory board, University of Nebraska Medical Center, Department of Medicine – University of Pamplona, Clinical Oncology, Society, Internal medicine, UNMC, College, Membership of the Royal College of Physicians of Ireland, Royal college, Nebraska Medicine, Division, Richard, University, American College of Physicians, Mayo Clinic, Cancer, Patient, American Association for Cancer Research, Transplant, Book, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Nursing, Medical device, Physician

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

Growing Crisis in Child Care Focus of Nebraska Conference

Retrieved on: 
Tuesday, September 19, 2023
Workforce, Learning, University, Nebraska Department of Economic Development, Human services, Parent, Policy, Global Communications Conference, Nebraska Department of Education, Research, Child care, Nebraska Department of Health & Human Services, National Association for the Education of Young Children, Omaha–Council Bluffs metropolitan area, Commerce, Economic development, Greater Omaha Chamber of Commerce, Growth, Conference, University of Nebraska Medical Center, Toy, Management, Child, Education

Jim Pillen will provide opening remarks, marking the first time the state’s highest-ranking official will speak at the conference.

Key Points: 
  • Jim Pillen will provide opening remarks, marking the first time the state’s highest-ranking official will speak at the conference.
  • At a time when 91% of counties in Nebraska do not have enough available licensed child care slots to meet current demand and 11 counties lack a single licensed provider, Nebraskans are coming together to help solve a growing child care and economic crisis.
  • “With as many as 80,000 jobs open in Nebraska, our child care crisis is an economic crisis.
  • This year’s event is coordinated and facilitated by the Buffett Early Childhood Institute and sponsored by First Five Nebraska, Nebraska Association for the Education of Young Children, the Nebraska Association of School Boards, Nebraska Business Development Center, Nebraska Chamber of Commerce and Industry, Nebraska Children and Families Foundation, Nebraska Community Foundation, Nebraska Department of Economic Development, Nebraska Department of Education, the Nebraska Department of Health and Human Services, the Nebraska Early Childhood Collaborative, Nebraska Early Learning Connection, Nebraska Economic Developers Association, Nebraska Extension, Panhandle Partnership, Inc., the Buffett Early Childhood Fund, and the Buffett Early Childhood Institute.

Berenberg Invitational Surpasses $2 Million In Funds Raised For Pancreatic Cancer Research

Retrieved on: 
Wednesday, September 20, 2023
Pancreatic cancer, Partnership, University, Club, University of Nebraska Medical Center, Nebraska Medicine, Serie A Football Club of the Year, Research, Golf, Biomarker, Name, Collection, Drug discovery, Pharmaceutical industry, Berenberg family

NEW YORK, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Berenberg, the world's second oldest bank, along with a collection of legendary professional golfers on the men's and women's tours, as well as business leaders, came together at GlenArbor Golf Club for the Berenberg Invitational to raise vital funds for the event's beneficiary, the University of Nebraska Medical Center and Nebraska Medicine.

Key Points: 
  • Our three-year partnership with the event's beneficiary is a microcosm of the impact golf can have in raising valuable funds for philanthropic causes, and in our case specifically, key research to find a cure for pancreatic cancer," said Berenberg Managing Partner, David Mortlock.
  • In total, this year's Berenberg Invitational raised $550,000 for pancreatic cancer research, bringing Berenberg's combined donation over three tournaments to $2,050,000.
  • "Each year we have been involved with the Berenberg Invitational has greatly impacted how quickly and efficiently we are able to conduct research focusing on the molecular complexities of pancreatic cancer geared towards finding a cure humanity desperately needs," said Dr. Sunil Hingorani, director of the UNMC Pancreatic Cancer Center of Excellence and Nebraska Medicine pancreatic cancer program.
  • Berenberg has held an annual charity golf event in New York featuring legends of the game for nearly a decade.

Prevent Blindness Declares Third Annual Inflammatory Eye Disease Awareness Week as Sept. 18 - 24

Retrieved on: 
Friday, September 15, 2023
University, Visual impairment, Graves' ophthalmopathy, Social media, Eye, Conjunctivitis, Nutrient, Nebraska Medicine, University of Nebraska Medical Center, Paratriathlon, Inflammation, Professor, Improvised explosive device, Keratitis, MD, Uvea, Risk, Rheumatoid arthritis, IED, Safety, Cosmetics, Pharmaceutical industry, Uveitis, Ophthalmology, Mallinckrodt

CHICAGO, Sept. 15, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has declared Sept. 18 – 24, 2023, as the third annual Inflammatory Eye Disease (IED) Awareness Week. IEDs include a range of conditions associated with eye inflammation.

Key Points: 
  • Prevent Blindness Offers Information on Inflammatory Eye Diseases, Including a New Video, Fact Sheets and Social Media Graphics, to Educate Public on Ways to Protect Vision and Prevent Unnecessary Vision Loss
    CHICAGO, Sept. 15, 2023 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading eye health and safety nonprofit organization, has declared Sept. 18 – 24, 2023, as the third annual Inflammatory Eye Disease (IED) Awareness Week.
  • Different types of IED include Uveitis , Keratitis , Conjunctivitis , Rheumatoid Arthritis , and Thyroid Eye Disease .
  • Prevent Blindness is also debuting a new episode in the online Focus on Eye Health Expert Series, " Uveitis and Inflammatory Eye Diseases ."
  • Jeff Todd, president and CEO of Prevent Blindness, interviews Steven Yeh, MD, Professor and Stanley Truhlsen Jr.

CEUS Underutilization May Pose Greater Risk Than Rare Side Effects Associated With Use, Say Experts

Retrieved on: 
Friday, September 8, 2023
Other Health, General Health, Radiology, Philanthropy, Oncology, Medical Devices, Hospitals, Foundation, Cardiology, Biotechnology, FDA, Other Philanthropy, Health, CT, Radiation, UEA, University, GE HealthCare, Beth Israel Deaconess Medical Center, University of Nebraska Medical Center, Neoplasm, CEUS, Agent handling, Nebraska Medicine, Brain, Kidney, Assistant, Harvard Medical School, Allergy, Patient, Risk, Internal medicine, ICUS, MUGA, Research, Echocardiography, Death, Conference, SPECT, Medical imaging, Medical device, Vaccine, Medicine

He noted that UEAs present a rare risk of a severe allergic reaction in 1/15,000 patients.

Key Points: 
  • He noted that UEAs present a rare risk of a severe allergic reaction in 1/15,000 patients.
  • By comparison, iodinated contrast agents used for CT present a risk of life threatening reactions in 1/500 to 1/5,000 patients.
  • “Despite the rare risk of an adverse event associated with UEAs, patients face an even greater risk associated with non-use,” said Dr. Tom Porter, lead author of the ICUS guidelines.
  • He also said that CEUS use has even been associated with a reduced length of hospital stay in some patients.

Phoenix Children's Expands Pediatric Orthopedic Surgery Team with Hire of Globally Renowned Brittle Bone Expert

Retrieved on: 
Monday, September 11, 2023
American Society for Bone and Mineral Research, Sports medicine, Missouri State University, University, Nationwide Children's Hospital, Body composition, University of Nebraska Medical Center, Phoenix Children's Hospital, Elective surgery, University of Nebraska–Lincoln, Quality of life, Hope, Nebraska Medicine, Osteoblast, Osteogenesis imperfecta, Collagen, type I, alpha 1, MBA, Research, Chronic kidney disease-mineral and bone disorder, National Association Medical Staff Services, Business administration, Jansen, Diving Medical Advisory Council, MD, Patient, Lincoln, Nebraska, Medical Center, Hospital, AI, Saint Louis University, Society, Dentistry, Nursing, Medical device, Orthopedic surgery, Child

Maegen Wallace, MD, MBA , a pediatric orthopedic surgeon and expert in osteogenesis imperfecta, or brittle bone disease, joined the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's last month.

Key Points: 
  • Maegen Wallace, MD, MBA , a pediatric orthopedic surgeon and expert in osteogenesis imperfecta, or brittle bone disease, joined the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's last month.
  • At the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's, Dr. Wallace will focus on lower-extremity issues, osteogenesis imperfecta and other rare skeletal diseases .
  • On the research front, she will continue her work to define best clinical practices for patients with brittle bone disease and uncover new treatment options.
  • "Phoenix Children's emphasis on research and the chance to work once again with Dr. Halanski are what drew me to Phoenix Children's," said Dr. Wallace.

Molekule's PECO technology demonstrates power of pollutant destruction in air purification

Retrieved on: 
Thursday, August 24, 2023
PALM, University, Florida International University, Allergy, Education, Atmosphere, History of Florida International University, Coronavirus, COVID-19, Organic compound, Nebraska Medicine, University of Nebraska Medical Center, Research, Molekule, Cell, Synthetic control method, Hospital, Mercyhealth, BEACH, Patient, Atmosphere of Earth, Smoke, Mouse, Ozone, Filtration, HEPA, Bacteria, PECO, FDA, Virus, Allergen, Environmental remediation, Vaccine, Pharmaceutical industry

PALM BEACH GARDENS, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq: MKUL), a leading air purification technology company, today announced new laboratory results that highlight the power of the Company’s proprietary photoelectrochemical oxidation (“PECO”) technology and its ability to destroy what conventional filters leave behind.

Key Points: 
  • Three new studies were completed, including one from Florida International University, that demonstrate that Molekule’s PECO technology can safely destroy a vast range of indoor air pollutants.
  • PECO technology for air purification reacts with ultraviolet light to oxidize pollutants, including viruses, bacteria, mold, ozone, allergens, volatile organic compounds, particles found in smoke and chemicals, and break them down into harmless molecules.
  • PECO technology not only captures but destroys pollutants at a microscopic scale, ultimately helping people who suffer from specific pollutant triggers breathe better air,” said Jaspreet Dhau, Molekule’s vice president and head of research and development.
  • For more information about how Molekule’s patented PECO technology detects and destroys organic pollutants, please visit molekule.com.

CropX Appoints John Gates as Chief Revenue Officer

Retrieved on: 
Wednesday, August 23, 2023
Climate, University, Senior, Farmer, The Climate Corporation, ISCB Senior Scientist Award, Growth, Gates, University of Nebraska Medical Center, Management

ANAHEIM, Calif., Aug. 23, 2023 /PRNewswire/ -- CropX, a global leader in digital solutions for agronomic farm management, today announced the appointment of agricultural technology veteran John Gates to Chief Revenue Officer (CRO). Gates will oversee CropX's commercial expansion globally following leadership roles in Europe and North America.  

Key Points: 
  • ANAHEIM, Calif., Aug. 23, 2023 /PRNewswire/ -- CropX , a global leader in digital solutions for agronomic farm management, today announced the appointment of agricultural technology veteran John Gates to Chief Revenue Officer (CRO).
  • CropX has a global vision to provide accessible and impactful technology to farmers everywhere with offices and employees located across five continents.
  • Gates will now lead global sales and revenue operations for CropX as CRO.
  • Before joining CropX, Gates served as the Chief Science Officer and Head of Product at CropMetrics, which was acquired by CropX.

Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023

Retrieved on: 
Monday, August 14, 2023
KOL, University, University of Nebraska Medical Center, Hypoplastic left heart syndrome, Doctor of Philosophy, Feinberg School of Medicine, Microsoft Exchange Server, MD, Patient, Medical Center, Medicine, Hospital, HLHS, Pharmaceutical industry

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET.

Key Points: 
  • MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET.
  • Click here to register and attend.
  • Company leadership will provide a pipeline update and insight into future directions.
  • All questions must be submitted prior to the event date by emailing your questions to: [email protected] or submitting them through the registration page by clicking here.

Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA

Retrieved on: 
Thursday, August 10, 2023
University, University of Nebraska Medical Center, Doctor of Philosophy, Nebraska Medicine, Babson College, MBA, Carroll School of Management, Cubist Pharmaceuticals, Boston College Law School, Pear, Ribon, Cell biology, Memorial, Merck, FDA, Therapy, Management, Auron, Biochemistry, Cerulean, Chemistry, Sanofi

Victoria Richon, Ph.D., was appointed to the company’s board of directors.

Key Points: 
  • Victoria Richon, Ph.D., was appointed to the company’s board of directors.
  • Christopher Guiffre, J.D., MBA, was appointed president and chief operating officer.
  • “We are thrilled to welcome Vicky and Chris to the Auron team during this exciting time for the company,” said Kate Yen, Ph.D., founder and chief executive officer of Auron.
  • Christopher Guiffre, J.D., MBA, joins Auron from Pear Therapeutics where he served as chief financial officer and chief operating officer since 2017.